Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$14.39-1.77%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CRVS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||||||
| R&D Expenses | 45.5 | 33.7 | 19.4 | 16.5 | 24.5 | 29.1 | 31.8 | 38.0 | 38.6 | 46.3 | 29.4 |
| Operating Income | (57.0) | (43.0) | (27.5) | (23.4) | (32.6) | (38.6) | (43.8) | (48.9) | (49.2) | (56.5) | (37.0) |
| Earnings from Continuing Operations | |||||||||||
| EBT, Incl. Unusual Items | (51.8) | (13.3) | (59.1) | (21.7) | (31.3) | (43.2) | (6.0) | (46.7) | (46.9) | (55.7) | (36.4) |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||||||
| Net Income | (54.1) | (15.3) | (62.3) | (27.0) | (41.3) | (43.2) | (6.0) | (46.7) | (46.9) | (55.7) | (36.4) |
| Per Share | |||||||||||
| Basic EPS | (0.59) | (0.19) | (1.02) | (0.56) | (0.89) | (1.03) | (0.20) | — | — | — | — |
| Diluted EPS | (0.59) | (0.53) | (1.02) | (0.56) | (0.89) | (1.03) | (0.20) | — | — | — | — |
| Basic Weighted Avg Shares | 92.4 | 79.0 | 61.0 | 48.0 | 46.6 | 41.9 | 29.5 | — | — | — | — |
| Diluted Weighted Avg Shares | 92.4 | 79.7 | 61.0 | 48.0 | 46.6 | 41.9 | 29.5 | — | — | — | — |
| Supplemental | |||||||||||
| EBITDA | — | (42.9) | (27.4) | (23.2) | (32.2) | (38.1) | (43.2) | (48.1) | (48.4) | (55.7) | — |
| EBIT | (57.0) | (43.0) | (27.5) | (23.4) | (32.6) | (38.6) | (43.8) | (48.9) | (49.2) | (56.5) | (37.0) |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.